Excellent Brain Partners With Scholas Occurrentes to Bring ADHD Neurofeedback Into Schools Worldwide

Neurofeedback company Excellent Brain has announced a partnership with Scholas Occurrentes, the international educational organization founded under the auspices of the Vatican, to introduce ADHD-focused neurofeedback training to schools and universities around the world. The collaboration signals a meaningful step toward mainstreaming brain-based cognitive interventions within institutional education settings — a domain that has historically been slow to adopt neurotechnology tools.

The Technology Behind the Partnership

Excellent Brain's platform is built around neurofeedback, a non-invasive technique in which users receive real-time feedback on their own brainwave activity, typically through an EEG-based headset, and learn to self-regulate neural patterns associated with attention and focus. In ADHD applications, the goal is to train users to increase activity in frequency bands linked to sustained attention while reducing patterns associated with inattentiveness and impulsivity. Unlike pharmacological interventions, neurofeedback requires no prescription and carries no systemic side effects, making it a particularly attractive option for school-age populations where stimulant medication remains a sensitive and often contested topic among parents and educators. Excellent Brain's system is designed to be accessible in non-clinical environments, a critical requirement for deployment at scale within educational infrastructure.

Why This Matters for Neurotechnology

Partnerships of this nature represent one of the clearest pathways for neurofeedback technology to achieve the kind of real-world penetration that laboratory performance alone cannot deliver. Scholas Occurrentes operates across more than 190 countries, giving Excellent Brain access to a global distribution network that most neurotechnology startups could not approach independently. For the broader industry, this deal illustrates a maturing commercialization strategy: rather than competing solely within the clinical channel alongside pharmaceutical and medical device incumbents, neurofeedback developers are increasingly identifying institutional partners in education, workplace wellness, and community health as viable go-to-market vectors. It also brings neurofeedback in front of a population — students with attention difficulties — for whom the evidence base has been steadily building over the past decade.

Market Context and the Road Ahead

The ADHD neurotechnology market sits at an interesting inflection point. Regulatory clarity has improved, consumer-grade EEG hardware has become considerably more affordable, and a growing body of peer-reviewed research has lent credibility to neurofeedback as a complementary or standalone intervention. At the same time, questions around standardization, practitioner training, and long-term outcome data continue to create friction for institutional buyers. The Excellent Brain and Scholas Occurrentes partnership will be closely watched as a test case for whether school-based neurofeedback can demonstrate measurable outcomes at scale — and if it can, the implications for how the broader neurotechnology industry approaches non-clinical distribution channels could prove transformative.